PressJuly 13, 2022 Albert Labs Files US Provisional Patent Application for Psilocybe And Other Mycelia
PressJuly 12, 2022 Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
PressJuly 8, 2022 Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
PressJuly 7, 2022 Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
BlogJuly 6, 2022 How Can Ancient Medicines Work with the Future of Medicine?: Mindshifting Moments – Stream #3
PressJuly 6, 2022 CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds
PressJuly 5, 2022 Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
BlogJuly 1, 2022 Field Trip’s Full Year 2022 Financial and Pipeline Analysis – Bullish vs Bearish: Episode #2
PressJuly 1, 2022 atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
BlogJune 29, 2022 Becca Williams Guides the Release of Emotional Turmoil Using Psychedelics – Podcast Episode #10
BlogJune 28, 2022 Damian Kettlewell, CEO of Clairvoyant Therapeutics, Sits in the Investor Hotseat – Stream #4
PressJune 28, 2022 Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA
